| scholarly article | Q13442814 |
| P50 | author | Pedram Hamrah | Q7159371 |
| Reza Dana | Q16206939 | ||
| Giulio Ferrari | Q42391130 | ||
| Ula V Jurkunas | Q59817045 | ||
| Mohammad H Dastjerdi | Q89228119 | ||
| Debra A Schaumberg | Q114406893 | ||
| Andre Okanobo | Q114572926 | ||
| P2093 | author name string | Francisco Amparo | |
| Leila Smaga | |||
| P2860 | cites work | Interleukin-1 in the pathogenesis and treatment of inflammatory diseases | Q24606766 |
| Prevalence of dry eye syndrome among US women | Q28196875 | ||
| Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. | Q30813799 | ||
| Doxycycline inhibition of interleukin-1 in the corneal epithelium. | Q30900518 | ||
| Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies | Q33720070 | ||
| Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway | Q33938235 | ||
| Characterization of effector T cells in dry eye disease | Q34065949 | ||
| The economic burden of dry eye disease in the United States: a decision tree analysis | Q34147677 | ||
| Corneal epithelial wound healing | Q34302886 | ||
| Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | Q34443357 | ||
| Impact of dry eye syndrome on vision-related quality of life | Q35741609 | ||
| Neural basis of sensation in intact and injured corneas | Q35755185 | ||
| Efficacy of topical blockade of interleukin-1 in experimental dry eye disease | Q36044544 | ||
| JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells | Q36380244 | ||
| Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. | Q36639890 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome | Q36676823 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. | Q37401805 | ||
| The international workshop on meibomian gland dysfunction: executive summary | Q37859542 | ||
| Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells | Q39890559 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases | Q41787535 | ||
| Impaired functional visual acuity of dry eye patients | Q42668504 | ||
| Estimating the prevalence of dry eye among Indian patients attending a tertiary ophthalmology clinic | Q43052456 | ||
| Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease | Q43723395 | ||
| Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury | Q44301453 | ||
| Evaluation of topical cyclosporine for the treatment of dry eye disease | Q44443222 | ||
| Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. | Q45930063 | ||
| Anion binding and controlled aggregation of human interleukin-1 receptor antagonist | Q46104923 | ||
| Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. | Q46478756 | ||
| Utility assessment among patients with dry eye disease. | Q53379868 | ||
| Unpreserved carboxymethylcellulose artificial tears evaluated in patients with keratoconjunctivitis sicca | Q67574582 | ||
| Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus | Q68005187 | ||
| Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea | Q68479664 | ||
| Detection of mRNA for the cytokines, interleukin-1 alpha and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy | Q72016880 | ||
| Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca | Q72993423 | ||
| Prevention of allergic eye disease by treatment with IL-1 receptor antagonist | Q73152150 | ||
| Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation | Q73234836 | ||
| Reliability and validity of the Ocular Surface Disease Index | Q73801624 | ||
| Wavefront analysis of higher order aberrations in dry eye patients | Q80182881 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury | Q84963644 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 715-723 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | JAMA Ophthalmology | Q4787301 |
| P1476 | title | Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial | |
| P478 | volume | 131 |
| Q64072411 | A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease |
| Q37417825 | A randomized controlled trial of omega-3 fatty acids in dry eye syndrome |
| Q35220614 | Aberrant interleukin-1 signalling does not increase susceptibility of mice to NOD2-dependent uveitis |
| Q38460976 | Advances in pharmacotherapy for allergic conjunctivitis |
| Q38886086 | Ageing and ocular surface immunity. |
| Q59136398 | Anakinra Therapy for Non-cancer Inflammatory Diseases |
| Q35863016 | Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study |
| Q37278726 | Bilateral corneal ulceration in ocular graft-versus-host disease |
| Q35678783 | Corneal sensitivity following lacrimal gland excision in the rat. |
| Q27676526 | Design of a superior cytokine antagonist for topical ophthalmic use |
| Q37242107 | Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells? |
| Q36250852 | Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab |
| Q34473772 | Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndrome |
| Q37359850 | Evaluation of patients with dry eye disease for conjunctival Chlamydia trachomatis and Ureaplasma urealyticum |
| Q33748628 | High Frequency of Latent Conjunctival C. trachomatis, M. hominis, and U. urealyticum Infections in Young Adults with Dry Eye Disease |
| Q26740643 | Immunomodulation on the ocular surface: a review |
| Q50599398 | Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. |
| Q35133812 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives |
| Q38197286 | Macrophages: important players in primary Sjögren's syndrome? |
| Q34028408 | Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. |
| Q43075719 | Neuropathic Corneal Pain: Approaches for Management |
| Q93341813 | Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo |
| Q38904210 | Ocular Manifestations of Inherited Phospholipase-Cγ2-Associated Antibody Deficiency and Immune Dysregulation |
| Q90371647 | Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT |
| Q36990254 | Targeting Imbalance between IL-1β and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas |
| Q52768652 | The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. |
| Q38219053 | The eye: a window of opportunity in rheumatoid arthritis? |
| Q90586597 | The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease |
| Q47563654 | The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis. |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
| Q47132797 | Therapies for Meibomian Gland Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q37195776 | Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. |
| Q37636664 | Treating inflammation by blocking interleukin-1 in humans |
| Q26799747 | Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies |
| Q38766815 | Understanding Neuropathic Corneal Pain--Gaps and Current Therapeutic Approaches |
Search more.